Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Amortization of Deferred Charges: 2020-2021

Historic Amortization of Deferred Charges for Apellis Pharmaceuticals (APLS) over the last 2 years, with Dec 2021 value amounting to $3,000.

  • Apellis Pharmaceuticals' Amortization of Deferred Charges fell 76.92% to $3,000 in Q4 2021 from the same period last year, while for Dec 2021 it was $113,000, marking a year-over-year decrease of 49.10%. This contributed to the annual value of $113,000 for FY2021, which is 49.10% down from last year.
  • Apellis Pharmaceuticals' Amortization of Deferred Charges amounted to $3,000 in Q4 2021, which was up 137.50% from -$8,000 recorded in Q3 2021.
  • Over the past 5 years, Apellis Pharmaceuticals' Amortization of Deferred Charges peaked at $125,000 during Q3 2020, and registered a low of -$8,000 during Q3 2021.
  • Its 2-year average for Amortization of Deferred Charges is $41,875, with a median of $20,000 in 2020.
  • Examining YoY changes over the last 5 years, Apellis Pharmaceuticals' Amortization of Deferred Charges showed a top increase of 96.49% in 2021 and a maximum decrease of 106.40% in 2021.
  • Over the past 2 years, Apellis Pharmaceuticals' Amortization of Deferred Charges (Quarterly) stood at $13,000 in 2020, then slumped by 76.92% to $3,000 in 2021.
  • Its Amortization of Deferred Charges was $3,000 in Q4 2021, compared to -$8,000 in Q3 2021 and $6,000 in Q2 2021.